Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenrong granules dose-finding placebo-controlled phase 2 trial in amyotrophic lateral sclerosis
ChiCTR2400083114Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Shenrong Granules in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Change from baseline in ALSFRS-R score after treatment. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Shenrong Granules
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2400083114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083114.